Skiplinks

Medicine put to the test

As an independent scientific institute, IQWiG examines the benefits and harms of medical interventions for patients. We provide information about the advantages and disadvantages of examination and treatment methods in the form of scientific reports and easily understandable health information.

Latest news

Press Releases

Press Releases

Mepolizumab in severe asthma: added benefit not proven

2016-05-02 Drug manufacturer deviated from the specifications of the comparator therapy in the direct comparison. The indirect comparison conducted by the manufacturer was unsuitable for an assessment.  read more Link to "Mepolizumab in severe asthma: added benefit not proven"

Ibrutinib: indication of added benefit in one of three therapeutic indications

2016-05-02 No added benefit proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug.  read more Link to "Ibrutinib: indication of added benefit in one of three therapeutic indications"

Umeclidinium for symptom relief in COPD: added benefit not proven

2016-05-02 No significant differences in comparison with the comparator therapy in patients with moderate severity. Drug manufacturer presented no study data for patients with more severe disease.  read more Link to "Umeclidinium for symptom relief in COPD: added benefit not proven"

DMP “rheumatoid arthritis”: guidelines cover important health care aspects

2016-04-28 IQWiG has identified guideline recommendations for a potential DMP: rehabilitation measures are only addressed sporadically; the focus is on drug therapy.  read more Link to "DMP “rheumatoid arthritis”: guidelines cover important health care aspects"

Bronchial carcinoma: added benefit of crizotinib for first-line treatment not proven

2016-04-01 In the only study of direct comparison, carboplatin in the control arm was not used in compliance with the Pharmaceutical Directive.  read more Link to "Bronchial carcinoma: added benefit of crizotinib for first-line treatment not proven"

loading …

Current commenting procedures (Hearings)

Current commenting procedures (Hearings)

No. Title Type Deadline
N15-12 Isolated application of fluoride varnish for initial caries lesions in primary teeth on the report plan 2016-06-17

Commissions advertised

Commissions advertised

Currently no commissions advertised.


Easily understandable information for patients and the general community

Umeclidinium (Incruse) for chronic obstructive pulmonary disease (COPD)

The drug umeclidinium (trade name: Incruse) has been approved since November 2015 for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults.  read more (Link to "Umeclidinium (Incruse) for chronic obstructive pulmonary disease (COPD)" – opens in a new window)

to top

Glossary entries